Pharmaceutical International News Archives - August 2011
Subscribe to SuppliersWeek 1 - August 2011
FDA Evital Emergency Contraceptive Warning
Posted by Pharmaceutical International's Senior Journalist on 15:15:00
The US FDA has issued a consumer warning covering Evital - an emergency birth control drug that's not been approved for use
Nicotine May Be Parkinson’s Protection Treatment
Posted by Pharmaceutical International's Drug Development Correspondent on 15:30:00
A new Parkinson's treatment discovery could lead to future drugs that target nicotine receptors in the human body
Drugs Can’t Treat New Salmonella Strain
Posted by Pharmaceutical International's Senior Journalist on 14:15:00
A new drug-resistant salmonella strain has emerged with the potential to become globally-distributed, scientists say
Statin Stroke Patient Heart Benefits
Posted by Pharmaceutical International's Senior Journalist on 16:55:00
Statins, typically prescribed to patients with high cholesterol, seems to offer benefits to specific young stroke victims, too
Week 2 - August 2011
NICE Rejects Multiple Sclerosis Drug Fingolimod
Posted by Pharmaceutical International's Senior Journalist on 15:50:00
Limited trial data and cost concerns prompt UK medical advisory body to reject novel oral MS drug treatment
MIT’s DRACO Drug Could Kill Nearly All Viruses
Posted by Pharmaceutical International's Drug Development Correspondent on 16:00:00
US researchers have developed a single drug with the potential to treat almost all viral infection types, including common colds and influen...
FDA Approval for Gilead HIV Drug Complera
Posted by Pharmaceutical International's Drug Development Correspondent on 16:05:00
US Food and Drug Administration clears Gilead Sciences' HIV drug Complera for use by patients in the United States, with some restrictions
Pfizer Begins Nigerian Trovan Drug Pay-Outs
Posted by Pharmaceutical International's Senior Journalist on 14:10:00
A case involving pharmaceutical firm Pfizer, the drug Trovan and a large number of Nigerian families has entered a new phase.